866-997-4948(US-Canada Toll Free)

Metastatic Hormone Refractory Prostate Cancer-Market Insights, Epidemiology and Market Forecast-2025

Published By :

DelveInsight

Published Date : Jul 2017

Category :

Pharmaceutical

No. of Pages : 70 Pages

DelveInsights Metastatic Hormone Refractory Prostate Cancer -Market Insights, Epidemiology and Market Forecast-2025 report provides an overview of the disease and in depth research related to Metastatic Hormone Refractory Prostate Cancer for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Metastatic Hormone Refractory Prostate Cancer . It enables understanding of the historical and forecasted epidemiological data for the diagnosed prevalent cases of Metastatic Hormone Refractory Prostate Cancer for 7 major markets.

The market outlook also provides understanding of country specific revenue and share by analyzing performance of the current therapies and thorough potential uptake of new products. Additionally, the Report highlights the frontrunners, the drivers and barriers for the Metastatic Hormone Refractory Prostate Cancer market, as well as treatment algorithm, current treatments & advancements are included.The chapters including marketed products highlights the advantages and disadvantages associated with therapies associated with Metastatic Hormone Refractory Prostate Cancer , providing an in-depth analysis of emerging therapies which will create an impact through their launch.

According to DelveInsight, the forecasted patient population of Metastatic Hormone Refractory Prostate Cancer for the year 2025 will be XX, increasing at a CAGR of XX% from 2015 to 2025 and the Metastatic Hormone Refractory Prostate Cancer 7MM market size is estimated to be USD XX by 2025.The DelveInsight Report will help in enhanced understanding of the Metastatic Hormone Refractory Prostate Cancer market from inside out, with transparency into the calculated patient forecasting data and estimated market size.

Key Coverage

Understanding historical and forecasted epidemiological data for Metastatic Hormone Refractory Prostate Cancer covering 7MM from 2015-2025.
Segment level epidemiology and market split for Metastatic Hormone Refractory Prostate Cancer .
The thorough assessment of competitors, market, current trends & treatments along with upcoming treatments for Metastatic Hormone Refractory Prostate Cancer .
The Report also covers the market size for 7MM (United States, EU 5 (Germany, Spain, Italy, France and United Kingdom) and Japan) from 2015-2025 and detailed historical and forecasted Metastatic Hormone Refractory Prostate Cancer market trends.
Thorough market distribution based on market share for Metastatic Hormone Refractory Prostate Cancer .

Reasons to buy

The report will help in developing business strategies by understanding trends shaping and driving the Metastatic Hormone Refractory Prostate Cancer market.
To understand the future market competition in the Metastatic Hormone Refractory Prostate Cancer market and Insightful review of the key market drivers and barriers.
Organize sales and marketing efforts by identifying the best opportunities for Metastatic Hormone Refractory Prostate Cancer in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.
Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.


1. Report Introduction
2. Metastatic Hormone Refractory Prostate Cancer Market Overview at a Glance
2.1. Total Market Share Distribution of Metastatic Hormone Refractory Prostate Cancer for 7 MM in 2016
2.2. Total Market Share Distribution of Metastatic Hormone Refractory Prostate Cancer for 7 MM in 2025
3. Metastatic Hormone Refractory Prostate Cancer
3.1.1. Overview
3.1.2. Symptoms
3.1.3. Pathophysiology
3.1.4. Staging
3.1.5. Diagnosis
3.1.6. Treatment
4. Epidemiology and Patient Population
4.1.1. United States
4.1.1.1. Diagnosed Cases of Metastatic Hormone Refractory Prostate Cancer in United States
4.1.2. Germany
4.1.2.1. Diagnosed Cases of Metastatic Hormone Refractory Prostate Cancer in Germany
4.1.3. France
4.1.3.1. Diagnosed Cases of Metastatic Hormone Refractory Prostate Cancer in France
4.1.4. Italy
4.1.4.1. Diagnosed Cases of Metastatic Hormone Refractory Prostate Cancer in Italy
4.1.5. Spain
4.1.5.1. Diagnosed Cases of Metastatic Hormone Refractory Prostate Cancer in Spain
4.1.6. United Kingdom
4.1.6.1. Diagnosed Cases of Metastatic Hormone Refractory Prostate Cancer in United Kingdom
5. Treatment Algorithm
5.1.1. Treatment Guidelines/Practices
6. Marketed Drugs for Metastatic Hormone Refractory Prostate Cancer
6.1. Drug 1: Company A
6.1.1. Drug Description
6.1.2. Mechanism of Action
6.1.3. Regulatory Milestones
6.1.4. Advantages & Disadvantages
6.1.5. Safety and Efficacy
6.1.6. Product Profile
6.1.7. Patent Status
6.2. Drug 2: Company B
6.2.1. Drug Description
6.2.2. Mechanism of Action
6.2.3. Regulatory Milestones
6.2.4. Advantages & Disadvantages
6.2.5. Safety and Efficacy
6.2.6. Product Profile
6.2.7. Patent Status
7. Emerging Therapies
7.1. Drug 3: Company C
7.1.1. Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Product Profile
7.1.5. Launch Date
7.1.6. Clinical Development
7.1.7. Clinical Pipeline Activity
7.1.8. Ongoing Trials Information
7.1.9. Clinical Trial by Phase
7.2. Drug 4: Company B
7.2.1. Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Product Profile
7.2.5. Launch Date
7.2.6. Clinical Development
7.2.7. Clinical Pipeline Activity
7.2.8. Ongoing Trials Information
7.2.9. Clinical Trial by Phase
8. Overview of Total Metastatic Hormone Refractory Prostate Cancer Market (2016 & 2025)
9. Metastatic Hormone Refractory Prostate Cancer : Country-Wise Market Analysis
9.1. United States
9.1.1. Historical Market Size (2015-2016)
9.1.2. Forecasted Market Size (2017-2025)
9.2. Germany Market Size
9.2.1. Historical Market Size (2015-2016)
9.2.2. Forecasted Market Size (2017-2025)
9.3. France Market Size
9.3.1. Historical Market Size (2015-2016)
9.3.2. Forecasted Market Size (2017-2025)
9.4. United Kingdom Market Size
9.4.1. Historical Market Size (2015-2016)
9.4.2. Forecasted Market Size (2017-2025)
9.5. Spain Market Size
9.5.1. Historical Market Size (2015-2016)
9.5.2. Forecasted Market Size (2017-2025)
9.6. Italy Market Size
9.6.1. Historical Market Size (2015-2016)
9.6.2. Forecasted Market Size (2017-2025)
9.7. Japan Market Size
9.7.1. Historical Market Size (2015-2016)
9.7.2. Forecasted Market Size (2017-2025)
10. Market Drivers
11. Market Restraints
12. Appendix
13. Report Methodology
14. Consulting Services
15. Disclaimer
16. About DelveInsight

List of Table

Table 1: Diagnosed Cases Metastatic Hormone Refractory Prostate Cancer in United States (2015-2025)
Table 2: Diagnosed Cases Metastatic Hormone Refractory Prostate Cancer in Germany (2015-2025)
Table 3: Diagnosed Cases Metastatic Hormone Refractory Prostate Cancer in France (2015-2025)
Table 4: Diagnosed Cases Metastatic Hormone Refractory Prostate Cancer in United Kingdom (2015-2025)
Table 5: Diagnosed Cases Metastatic Hormone Refractory Prostate Cancer in Spain (2015-2025)
Table 6: Diagnosed Cases Metastatic Hormone Refractory Prostate Cancer in Italy (2015-2025)
Table 7: Diagnosed Cases Metastatic Hormone Refractory Prostate Cancer in Japan (2015-2025)
Table 8: List of Marketed Drugs for Metastatic Hormone Refractory Prostate Cancer
Table 9: List of Pipeline Phase III Drugs for Metastatic Hormone Refractory Prostate Cancer
Table 10: Drug 1, Clinical Trials by Zone, 2017
Table 11: Clinical Trials by Trial status, 2017
Table 12: Drug 2, Clinical Trials by Zone, 2017
Table 13: Clinical Trials by Trial status, 2017
Table 14: Drug 3, Clinical Trials by Zone, 2017
Table 15: Clinical Trials by Trial status, 2017
Table 16: United States Market Size of Metastatic Hormone Refractory Prostate Cancer in USD, Million (2015-2025)
Table 17: Germany Market Size of Metastatic Hormone Refractory Prostate Cancer in USD, Million (2015-2025)
Table 18: France Market Size of Metastatic Hormone Refractory Prostate Cancer in USD, Million (2015-2025)
Table 19: United Kingdom Market Size of Metastatic Hormone Refractory Prostate Cancer in USD, Million (2015-2025)
Table 20: Spain Market Size of Metastatic Hormone Refractory Prostate Cancer in USD, Million (2015-2025)
Table 21: Italy Market Size of Metastatic Hormone Refractory Prostate Cancer in USD, Million (2015-2025)
Table 22: Japan Market Size of Metastatic Hormone Refractory Prostate Cancer in USD, Million (2015-2025)

List of Chart

July, 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *